Clinical Nuclear Medicine

Skip Navigation LinksHome > May 2013 - Volume 38 - Issue 5 > Distinguishing Pseudoprogression From Progression in High-Gr...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318286c148
Interesting Images

Distinguishing Pseudoprogression From Progression in High-Grade Gliomas: A Brief Review of Current Clinical Practice and Demonstration of the Potential Value of 18F-FDG PET

Oborski, Matthew J. MS*; Laymon, Charles M. PhD*; Lieberman, Frank S. MD; Mountz, James M. MD, PhD*

Collapse Box


Abstract: We report a case in which 18F-FDG PET was able to discriminate pseudoprogression from progression observed on contrast-enhanced (CE) MRI (CE-MRI). A 56-year-old male patient with anaplastic oligodendroglioma demonstrated markedly increased tumor enhancement on CE-MRI 1 month after completing radiation therapy (RT), suggesting radiological progression. However, the patient was clinically improved and therefore received an early-therapy response assessment PET to assess for pseudoprogression. PET showed low tumor uptake indicating stable disease. Follow-up CE-MRI at 3 and 4 months post-RT confirmed stable disease. This case emphasizes the value of 18F-FDG PET when pseudoprogression is clinically suspected.

© 2013 by Lippincott Williams & Wilkins


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.